Comparing the current results to its competitors, Adicet Bio Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.45 %, recorded in the same quarter.
Adicet Bio Inc 's Comment on Competition and Industry Peers
The company operates in the T cell therapy sector, facing competition from firms developing both allogeneic and autologous T cell therapies. Competitors in allogeneic immune cell therapy include CRISPR Therapeutics AG, Fate Therapeutics, Inc., Nkarta, Inc., Century Therapeutics, Inc., Allogene Therapeutics, Inc., and Legend Biotech. In the autologous T-cell therapy segment, competitors include Novartis AG, Bristol-Myers Squibb Company, and Autolus Therapeutics. The company utilizes gamma delta T cell technology and is developing proprietary manufacturing methods, the ability to expand specific T cell subpopulations, and in-house CAR target identification. It is also working on scalable manufacturing processes and holds intellectual property that may be subject to challenges from competitors.
April 29, 2025
Redwood City, Calif. and Boston In a significant development in the biotechnology sector, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company specializing in the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced the acceptance of an abstract for presentation at the esteemed American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting. This event, one of the most anticipated gatherings in gene and cell therapy, is scheduled to take place from May 13-17, 2025, in New Orleans, Louisiana. Presentation Details Highlighting ADI-270: Adicet Bio s oral presentation will focus on the preclinical data related to ADI-270, which could ...
February 27, 2025
Redwood City, CA and Boston In a significant development for patients suffering from systemic sclerosis (SSc), Adicet Bio, Inc. (Nasdaq: ACET), a pioneering clinical-stage biotechnology firm, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational therapy, ADI-001. This designation is aimed at facilitating the development and expediting the review process for promising therapies intended for serious conditions. The recognition comes at a crucial time as Adicet Bio strives to make strides in the realm of allogeneic gamma delta T cell therapies targeting autoimmune diseases and cancer.Systemic sclerosis, an autoimmune disorder characterized by ...
December 19, 2024
Adicet Bio, Inc. a pioneering biotechnology firm focused on the development of allogeneic gamma delta T cell therapies, has made significant strides in the fight against cancer and autoimmune diseases with the recent initiation of two groundbreaking clinical initiatives. With excitement building in the immunotherapy landscape, the company has announced the dosing of its first patient in the Phase 1 clinical trial of ADI-270 for patients suffering from metastatic or advanced clear cell renal cell carcinoma (ccRCC). This important milestone underscores Adicet s commitment to developing innovative treatment options for patients whose conditions are often resistant to conventional therapies.The Phase 1 trial of ...
October 16, 2024
Adicet Bio Secures FDA Approval for Pioneering Trials of ADI-001 in Rare Autoimmune Disorders: Idiopathic Inflammatory Myopathy and Stiff Person Syndrome to ADI-001 and Its Potential Impact In an exciting development for the treatment of rare autoimmune disorders, Adicet Bio, Inc. a leading clinical-stage biotechnology firm, has successfully secured approval from the United States Food and Drug Administration (FDA) to amend its Investigational New Drug (IND) application. This amendment will allow the evaluation of ADI-001, a promising allogeneic gamma delta T cell therapy, for the treatment of idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS). Probing the Impressive Technology Behind A...
International Stem Cell Corporation Share Performance
+2.27%
30 Days
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
Nkarta Inc is a biotechnology company with a business model centered on developing and commercializing engineered natural killer (NK) cell therapies for cancer patients. By utilizing proprietary technologies and expertise in genetic engineering, the company aims to enhance the therapeutic potential of NK cells and address unmet needs in the field of oncology. Nkarta Inc focuses on research, development, and production of these advanced cell therapies, collaborating with partners and regulators to bring innovative treatments to patients.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Adicet Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adicet Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
